Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Interpace's thyroid tests lift quarterly sales 18%; pancreatic test stays off the revenue line

Interpace Biosciences posted $10.4M in third-quarter revenue and positive adjusted EBITDA, but one-off charges produced a loss and its pancreatic test is not expected to sell before 2028.

17 Nov 2026 · Interpace Biosciences, Inc. IDXG · Company news

Interpace Biosciences now depends commercially on two thyroid tests. The company reported third-quarter 2026 revenue of $10.4M on 16 November, 18% higher than a year earlier. It credited ThyGeNEXT and ThyraMIR v2, whose combined test volume rose 7%.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Interpace Biosciences, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →